Tarceva erlotinib regulatory update

On Sept. 13, FDA's Oncologic Drugs Advisory Committee (ODAC) will review an sNDA for Tarceva erlotinib plus gemcitabine chemotherapy to treat first-line advanced pancreatic cancer. The sNDA has Priori...